92535aaf-b858-4843-ab2f-6bafb8ee0e02.jpeg
+2 more
Explain this case and suggest me a discharge medication
analyse_media
analyse_media
analyse_media
Reading File
Finding Sources
Searching PubMed
"cellulitis" AND "antibiotic" AND "treatment"
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Reading File
I now have comprehensive data from all three images and the textbooks. Let me compile the full case summary and discharge medication plan.
Case Summary: Ramesh - Grade II Cellulitis
Patient Profile
| Parameter | Details |
|---|---|
| Name | Ramesh |
| Age | 52 years, Male |
| Ward | General Surgery |
| DOA | 28/07/26 |
| Height/Weight | 162 cm / 65 kg |
Chief Complaint
Ulcer over the left lower leg x 5 years - developed after a door-fall injury, progressively worsening. Serous, foul-smelling, scanty discharge present. No loss of sensation in leg.
Significant Past History
- Left-sided CVA - 4 months ago
- Type 2 Diabetes Mellitus (T2DM) - on treatment
- Systemic Hypertension (SHTN) - on treatment
- No prior surgeries, no known drug allergies
Vitals on Admission
| Parameter | Value | Interpretation |
|---|---|---|
| Pulse | 104/min | Tachycardia |
| BP | 130/80 mmHg | Acceptable (on antihypertensives) |
| Temperature | 97°F | Afebrile / Low-grade |
| RR | 16/min | Normal |
| SpO₂ | 99% RA | Normal |
Systemic Examination
- CVS: S1, S2 heard, no added sounds
- RS: Normal vesicular breath sounds
- CNS: No focal neurological deficit (residual CVA status)
- Abdomen: Soft
Investigations
Hematology
| Parameter | Value | Reference | Interpretation |
|---|---|---|---|
| Hb | 11.1 g/dL | 13.5-16.5 | Low - Mild Anemia |
| PCV | 32.2% | 38-52 | Low |
| RBC | 3.98 × 10⁶/µL | 4.5-5.9 | Low |
| MCV | 80.9 fL | 80-98 | Normal |
| MCH | 27.9 pg | 26-34 | Normal |
| MCHC | 34.5 g/dL | 32-36 | Normal |
| RDW-CV | 13.2% | 11.5-13.1 | Slightly elevated |
| Total WBC | 15.92 × 10³/µL | 4-11 | Leukocytosis |
| Neutrophils | 79.4% | 40-75 | Neutrophilia |
| Lymphocytes | 15.0% | 20-40 | Low |
| ANC | 12.54 × 10³/µL | 1.5-8.5 | Markedly elevated |
Key finding: Leukocytosis with neutrophilia - confirms active bacterial infection.
Renal Function Tests
| Parameter | Value | Reference | Interpretation |
|---|---|---|---|
| Creatinine | 1.5 mg/dL | 0.7-1.4 | Mildly elevated |
| Sodium | 133 mEq/L | 136-145 | Mild hyponatremia |
| Potassium | 3.3 mEq/L | 3.5-5.1 | Low-normal / borderline |
| Chloride | 99.0 mEq/L | 97-111 | Normal |
Important: Mild renal impairment - relevant for antibiotic dosing.
Liver Function Tests
| Parameter | Value | Reference | Interpretation |
|---|---|---|---|
| Total Bilirubin | 3.2 mg/dL | 0.2-1.2 | Elevated - requires monitoring |
| Total Protein | 7.1 g/dL | 6.5-8.5 | Normal |
Provisional Diagnosis
Grade II Cellulitis of the left lower leg - superimposed on a chronic venous/traumatic ulcer in a diabetic, hypertensive patient with recent CVA.
In-Hospital Treatment Chart (as documented)
| Drug | Dose | Frequency |
|---|---|---|
| Inj. Cefoperazone-Sulbactam | 1.5 g IV | 1-0-1 (BD) |
| Inj. PAN (Pantoprazole) | 40 mg IV | 1-0-0 |
| Inj. Para (Paracetamol) | 1 g IV | 1-1-1 |
| T. Hyuoral Forte (Hyaluronic acid + Vitamin C) | - | 1-1-1 |
| T. IBzelwig (likely Itopride or B-complex) | - | 1-0-1 |
| T. Astan | - | 1-0-0 |
| T. Becollo (likely B-complex) | 100 mg | 1-0-0 |
| T. Amlodipine | 5 mg | 1-0-0 |
Discharge Medication Plan
Based on the in-hospital response, comorbidities (T2DM, HTN, recent CVA, mild renal impairment, elevated bilirubin), the following oral step-down discharge regimen is appropriate:
(References: ROSEN's Emergency Medicine; Textbook of Family Medicine 9e; per IDSA cellulitis guidelines and recent network meta-analysis of cellulitis antibiotics, PMID 39240378)
1. Antibiotic (Step-down from IV Cefoperazone-Sulbactam)
Tab. Amoxicillin-Clavulanate 625 mg (500/125 mg) - 1-0-1 x 7 days
- Rationale: Covers Streptococcus and Staphylococcus (the two main cellulitis pathogens). Appropriate step-down after parenteral beta-lactam/beta-lactamase inhibitor therapy. Mild renal impairment (Cr 1.5) - this dose is acceptable but reduce frequency if CrCl < 30.
- If MRSA risk is suspected: Tab. Clindamycin 300 mg TDS x 7 days is an alternative.
2. Diabetic Management
Tab. Metformin 500 mg - 1-0-1 with meals (if tolerating orally; hold if CrCl drops further - monitor creatinine)
- OR coordinate with existing antidiabetic regimen from prior treating physician
- Target perioperative/discharge glucose < 200 mg/dL
- Strict blood glucose monitoring at home
3. Antihypertensive (continue existing)
Tab. Amlodipine 5 mg - 1-0-0 (continue as inpatient)
- Patient's BP well-controlled at 130/80 - continue same dose
- If the patient was also on any other antihypertensive (e.g., ARB/ACE-I) for post-CVA care, continue those as per neurology advice
4. Antiplatelet (Post-CVA - likely already on this)
Tab. Aspirin 75 mg - 0-1-0 (after food) OR Tab. Clopidogrel 75 mg - 1-0-0
- Patient had a left CVA 4 months ago - antiplatelet therapy is standard unless contraindicated. Verify current neuro prescription.
5. Gastroprotection
Tab. Pantoprazole 40 mg - 1-0-0 (before breakfast) x 14 days
- Continue PPI coverage, especially with antibiotics + aspirin combination
6. Wound Care Instructions (Non-pharmacological - per 2025 systematic review, PMID 40530782)
- Limb elevation - keep left leg elevated above heart level when resting (reduces edema and speeds healing)
- Daily wound dressing - clean with normal saline, apply antiseptic (povidone-iodine or chlorhexidine) dressing
- Compression bandaging if venous insufficiency suspected (post-wound healing phase)
- Strict glucose control to improve wound healing
- Avoid walking barefoot; use protective footwear
7. Micronutrient Supplementation
Tab. B-complex with Vitamin C - 1-0-0 x 4 weeks
- Supports wound healing, immune function (patient has mild anemia and chronic ulcer)
Iron Supplementation (for mild normocytic anemia)
Tab. Ferrous sulfate 200 mg - 0-1-0 (between meals) x 4-6 weeks
- Hb 11.1 g/dL with chronic ulcer and possible nutritional deficiency - oral iron is appropriate
Monitoring Instructions at Discharge
| Parameter | When |
|---|---|
| Blood glucose (fasting + PP) | Daily |
| Blood pressure | Daily |
| Wound inspection | Every 2 days |
| Repeat Creatinine + LFT | At 1-week follow-up |
| Return to hospital if: | Fever, spreading redness, blistering, pain worsening, pus |
Red Flags - Return Immediately if:
- Temperature > 38.5°C (fever)
- Rapid spread of erythema beyond marked borders
- Development of blistering, bullae, or blackening (risk of necrotizing fasciitis)
- Decreased urine output (acute kidney injury)
- Confusion or new neurological symptoms (post-CVA watch)
Summary of Discharge Prescription:
| # | Drug | Dose | Frequency | Duration |
|---|---|---|---|---|
| 1 | Tab. Amoxicillin-Clavulanate | 625 mg | BD (after food) | 7 days |
| 2 | Tab. Pantoprazole | 40 mg | OD (before breakfast) | 14 days |
| 3 | Tab. Amlodipine | 5 mg | OD | Continue |
| 4 | Tab. Aspirin/Clopidogrel | 75 mg | OD | Continue (per neuro advice) |
| 5 | Tab. Metformin | 500 mg | BD | Continue |
| 6 | Tab. B-complex + Vit C | - | OD | 4 weeks |
| 7 | Tab. Ferrous sulfate | 200 mg | OD | 4-6 weeks |
Clinical note: The mildly elevated creatinine (1.5 mg/dL) and elevated total bilirubin (3.2 mg/dL) require follow-up at 1 week to check for drug-induced changes. The post-CVA status mandates antiplatelet continuation and BP control. Given the 5-year chronic ulcer history with T2DM, long-term wound care and podiatry/vascular surgery review should be arranged.
7fc6f411-22f7-4be7-a703-34673233060e.jpeg
What could be the 5 and 7 table
analyse_media
Finding Sources
Finding Sources
Searching the Web
Adving tablet generic name India brand aceclofenac OR "Adving tab"
Looking carefully at the image again combined with the analysis, here's what I can read:
From the drug regimen table:
| S.No | Dosage Form | Brand Name | Generic Name | Dose & Frequency | Start Date |
|---|---|---|---|---|---|
| 1 | Inj | Magnex | Cefoperazone + Sulbactam | 1.5g, 1-0-1 | 28/7 |
| 2 | Inj | Pan | Pantoprazole | 40mg, 1-0-1 | 28/7 |
| 3 | Inj | Para | Paracetamol (Acetaminophen) | 1g, 1-0-1 | 28/7 |
| 4 | Tab | Chymoral Forte | Trypsin + Chymotrypsin | 1-1-1 | 28/7 |
| 5 | Tab | Adving / Adolvig | Aceclofenac | 1-0-1 | 28/7 |
| 6 | Tab | Astan | Acetofen / Aceclofenac combination | 1-0-0 | 28/7 |
| 7 | Tab | Poallo / Panllo | Pantoprazole + Levosulpiride | Levoq 1-0-0 | 28/7 |
| 8 | Tab | Amlag / Amlodipine | Amlodipine | 5mg, 1-0-0 | 28/7 |
S.No 5 - Tab "Adving/Adolvig" → Aceclofenac
Generic Name: Aceclofenac (100 mg typically)
What it is: A second-generation NSAID (Non-Steroidal Anti-Inflammatory Drug), structurally related to diclofenac. It inhibits COX-2 more selectively than older NSAIDs and also inhibits interleukin-1β (IL-1β) production.
Why it's prescribed here:
- Post-injury/ulcer pain relief
- Reduces local soft tissue inflammation around the cellulitis site
- Better GI tolerability than diclofenac
Frequency: 1-0-1 (twice daily, after food)
Caution in this patient:
- Creatinine is mildly elevated (1.5 mg/dL) - use with caution, ensure adequate hydration; NSAIDs can worsen renal function
- Should be taken strictly after food
- Covered by PPI (pantoprazole) for GI protection
S.No 7 - Tab "Poallo/Panllo" → Pantoprazole + Levosulpiride (Panlo / similar brand)
Generic Name: Pantoprazole 40 mg + Levosulpiride 75 mg
What it is: A combination of:
- Pantoprazole (PPI) - suppresses gastric acid by irreversibly inhibiting H⁺/K⁺-ATPase proton pump
- Levosulpiride (prokinetic + antidopaminergic) - enhances gastric motility, reduces bloating and nausea, has mild antiemetic properties
Why it's prescribed here:
- Gastroprotection against the NSAIDs (aceclofenac S.No 5) and antibiotics (cefoperazone-sulbactam)
- Levosulpiride component addresses gastric discomfort, nausea, or dyspepsia that can occur with IV antibiotics
- Also protects against stress ulceration during hospitalization
Frequency: 1-0-0 (once daily, before breakfast)
Important Notes for This Patient
| Drug | Concern |
|---|---|
| S.No 5 (Aceclofenac) | Use cautiously - creatinine 1.5 mg/dL; monitor renal function. Stop if urine output decreases. |
| S.No 7 (Pantoprazole + Levosulpiride) | Levosulpiride can rarely cause extrapyramidal side effects - important to monitor in a post-CVA patient who may already have motor deficits |
The combination makes clinical sense: the NSAID (S.No 5) provides anti-inflammatory and analgesic benefit for the cellulitis/wound pain, while the PPI+prokinetic (S.No 7) provides a protective cover for the upper GI tract.
Based on the case how long the patient is admitted
Based on the case documents already analysed, here is what we know:
Duration of Admission
| Parameter | Detail |
|---|---|
| Date of Admission (DOA) | 28/07/2026 |
| Date of Discharge (DOD) | Not filled / Blank |
What the case tells us
The DOD field on the case sheet was left blank, which means at the time this case record was written up, the patient had not yet been discharged - the case was documented on the day of admission itself (28/07/26), which is also the start date of all medications in the drug chart.
Expected Duration Based on Clinical Parameters
For Grade II Cellulitis with this patient's comorbidities (T2DM, hypertension, post-CVA, mildly elevated creatinine), the typical inpatient stay would be:
| Scenario | Expected Stay |
|---|---|
| Good response to IV antibiotics | 5 - 7 days |
| Slow response (due to T2DM, chronic ulcer) | 7 - 14 days |
| Complications (spreading infection, worsening renal function) | Extended beyond 14 days |
Criteria for Discharge in This Case
The patient would typically be ready for discharge when:
- Leukocytosis resolves - WBC returning toward normal (currently 15.92 × 10³/µL)
- Wound discharge stops or significantly reduces
- Tachycardia resolves (currently PR 104/min)
- Tolerating oral antibiotics - step-down from IV cefoperazone-sulbactam
- Blood glucose controlled (T2DM management optimized)
- Creatinine stable or improving
In short: The DOD is blank because the patient was still admitted when the case was documented. Based on the clinical picture - Grade II cellulitis with T2DM - an estimated 7-10 days of inpatient stay would be expected before safe discharge on oral antibiotics.
What is the goal of therapy
Based on Ramesh's complete clinical picture, here are the goals of therapy:
Goals of Therapy — Ramesh, 52M, Grade II Cellulitis
1. PRIMARY GOAL — Eradicate the Infection
| Target | Measurable Endpoint |
|---|---|
| Eliminate bacterial infection (Strep/Staph) from the left lower leg | WBC normalizes (< 11 × 10³/µL) |
| Resolve neutrophilia | Neutrophils return to < 75% |
| Clear wound discharge | No serous/foul discharge from ulcer |
| Reduce local signs of cellulitis | No erythema, warmth, swelling, tenderness |
| Normalize pulse rate | PR < 100/min (currently tachycardic at 104/min) |
2. WOUND HEALING GOAL
| Target | Measurable Endpoint |
|---|---|
| Promote healing of the chronic 5-year ulcer | Reduction in ulcer size and depth |
| Prevent secondary infection or necrosis | No new discharge, no blackening/eschar |
| Prevent progression to necrotizing fasciitis | No crepitus, no rapid spread of erythema |
| Achieve clean wound bed | Granulation tissue formation visible |
3. COMORBIDITY CONTROL GOALS
Diabetes (T2DM)
| Target | Measurable Endpoint |
|---|---|
| Optimize blood glucose | Fasting glucose 80-130 mg/dL; Post-prandial < 180 mg/dL |
| Prevent hyperglycemia-driven immune suppression | HbA1c target < 7% long term |
| Prevent delayed wound healing due to poor glycemic control | Wound progressing toward closure |
Hypertension
| Target | Measurable Endpoint |
|---|---|
| Maintain BP control | BP < 130/80 mmHg (already at target) |
| Prevent end-organ damage | No new cardiac/renal events |
Post-CVA (4 months ago)
| Target | Measurable Endpoint |
|---|---|
| Prevent recurrent stroke | BP controlled, antiplatelet therapy continued |
| No new neurological deterioration | Stable CNS exam (NFND maintained) |
4. RENAL PROTECTION GOAL
| Target | Measurable Endpoint |
|---|---|
| Prevent worsening of mild renal impairment | Creatinine stable or improving (currently 1.5 mg/dL) |
| Avoid nephrotoxic combinations | Careful use of NSAIDs; monitor with IV antibiotics |
| Correct mild hyponatremia | Sodium returns to 136-145 mEq/L (currently 133) |
| Correct borderline hypokalemia | Potassium returns to 3.5-5.1 mEq/L (currently 3.3) |
5. HEPATIC MONITORING GOAL
| Target | Measurable Endpoint |
|---|---|
| Monitor elevated bilirubin | Total bilirubin returns toward normal (currently 3.2 mg/dL - high) |
| Rule out drug-induced liver injury | LFTs checked at 1-week follow-up |
| Avoid hepatotoxic drugs | Review all medications for hepatic metabolism burden |
6. ANEMIA CORRECTION GOAL
| Target | Measurable Endpoint |
|---|---|
| Correct mild anemia | Hb improves toward > 13 g/dL (currently 11.1 g/dL) |
| Address nutritional deficiency contributing to poor healing | Iron/Vitamin supplementation initiated |
7. SAFE STEP-DOWN AND DISCHARGE GOAL
| Target | Measurable Endpoint |
|---|---|
| Transition from IV to oral antibiotics | Patient tolerating oral amoxicillin-clavulanate |
| Achieve clinical stability | Afebrile, vitals normal, wound improving |
| Educate patient on self-care | Wound care, glucose monitoring, limb elevation |
| Prevent recurrence | Address risk factors - diabetes control, footwear, hygiene |
8. LONG-TERM PREVENTION GOAL
| Target | Action |
|---|---|
| Prevent recurrent cellulitis | Optimize glycemic control, treat underlying venous insufficiency |
| Vascular/surgical review | Rule out peripheral arterial disease (PAD) as cause of non-healing ulcer |
| Consider prophylactic antibiotics | If recurrent cellulitis (> 2 episodes/year) - Penicillin V or Erythromycin prophylaxis |
Summary in One Line Per Drug
| Drug | Goal of Therapy |
|---|---|
| Inj. Cefoperazone-Sulbactam | Kill causative bacteria; eliminate active cellulitis infection |
| Inj. Pantoprazole | Protect gastric mucosa from stress and antibiotic-related irritation |
| Inj. Paracetamol | Reduce fever, control pain - symptomatic relief |
| Tab. Chymoral Forte | Reduce soft tissue edema and inflammation; speed wound healing |
| Tab. Aceclofenac | Anti-inflammatory - reduce local wound inflammation and pain |
| Tab. Pantoprazole + Levosulpiride | Gastroprotection + prevent nausea/dyspepsia from antibiotics/NSAIDs |
| Tab. Amlodipine | Control hypertension - prevent end-organ damage, reduce stroke risk |
3839937f-1d3f-443d-83d9-ed7e5743eb91.jpeg
Tell me about the drug drug interaction and drug food interaction
analyse_media
Finding Sources
Finding Sources
Now I have the confirmed drug list from the image. The updated chart clearly shows:
- Inj. Magnex - Cefoperazone + Sulbactam 1.5g BD
- Inj. Pan - Pantoprazole 40mg OD
- Inj. Para - Acetaminophen (Paracetamol) 1g TDS
- Tab. Chymoral Forte - Trypsin + Chymotrypsin TDS
- Tab. Gremer - Glimepiride 500mg BD (this corrects earlier reading - it's a sulfonylurea for his T2DM)
- Tab. Aston - Aceclofenac 100mg OD
- Tab. Papulo - Palmitoylethanolamide (PEA) 100mg OD (neuropathic pain/anti-inflammatory)
- Tab. Amlog - Amlodipine 5mg OD
Drug-Drug Interactions (DDI)
🔴 MAJOR / CLINICALLY SIGNIFICANT
1. Glimepiride + Aceclofenac (NSAID)
| Parameter | Detail |
|---|---|
| Severity | Major |
| Mechanism | NSAIDs (aceclofenac) displace sulfonylureas from plasma protein binding sites AND inhibit renal prostaglandins, reducing renal glimepiride clearance |
| Effect | Enhanced hypoglycemic effect - risk of severe hypoglycemia |
| Monitoring | Monitor blood glucose closely; watch for sweating, tremors, confusion, palpitations |
| Action | Use lowest effective dose of aceclofenac; monitor glucose 2-hourly |
2. Aceclofenac + Amlodipine (NSAID + CCB)
| Parameter | Detail |
|---|---|
| Severity | Moderate |
| Mechanism | NSAIDs cause sodium and water retention via inhibition of renal prostaglandins, opposing the vasodilatory effect of amlodipine |
| Effect | Reduced antihypertensive efficacy of amlodipine; BP may rise |
| Monitoring | Monitor BP daily; watch for edema in the lower leg (already has cellulitis + ulcer) |
| Action | Limit NSAID duration; maintain BP monitoring |
3. Cefoperazone-Sulbactam + Paracetamol
| Parameter | Detail |
|---|---|
| Severity | Minor-Moderate |
| Mechanism | Both are hepatically metabolized; concurrent use in a patient with already elevated bilirubin (3.2 mg/dL) increases hepatic burden |
| Effect | Potential additive hepatotoxicity - especially concerning given this patient's elevated bilirubin |
| Monitoring | Monitor LFTs; watch for jaundice, dark urine, RUQ pain |
| Action | Limit paracetamol to ≤ 2g/day in this patient; monitor LFTs |
4. Glimepiride + Cefoperazone (Antibiotic)
| Parameter | Detail |
|---|---|
| Severity | Moderate |
| Mechanism | Beta-lactam antibiotics can unpredictably affect glucose metabolism; some antibiotics potentiate insulin secretion or enhance glimepiride effect |
| Effect | Risk of hypoglycemia during antibiotic course |
| Monitoring | Monitor blood glucose BD-TDS during IV antibiotic therapy |
🟡 MODERATE
5. Pantoprazole + Glimepiride
| Parameter | Detail |
|---|---|
| Severity | Moderate |
| Mechanism | PPIs inhibit CYP2C19 enzyme, which is involved in glimepiride metabolism |
| Effect | Increased glimepiride plasma levels → enhanced hypoglycemia risk |
| Monitoring | Blood glucose monitoring; watch for hypoglycemia symptoms |
6. Aceclofenac + Paracetamol
| Parameter | Detail |
|---|---|
| Severity | Minor |
| Mechanism | Additive analgesic effect (generally beneficial) but combined use can increase GI irritation |
| Effect | Increased GI mucosal irritation; additive analgesic benefit |
| Management | Covered by pantoprazole; acceptable combination short-term |
7. Trypsin-Chymotrypsin (Chymoral Forte) + Anticoagulants / Antibiotics
| Parameter | Detail |
|---|---|
| Severity | Minor |
| Mechanism | Proteolytic enzymes may enhance absorption of co-administered drugs by improving tissue penetration |
| Effect | May slightly enhance antibiotic penetration into infected tissue (actually beneficial here); mild platelet effect |
| Monitoring | No major concern in this regimen |
Drug-Food Interactions (DFI)
| Drug | Food Interaction | Effect | Recommendation |
|---|---|---|---|
| Glimepiride | Alcohol | Potentiates hypoglycemia, causes flushing (disulfiram-like reaction) | Strictly avoid alcohol |
| Glimepiride | High-sugar / high-carb meals | Unpredictable glucose spikes affecting drug efficacy | Take 30 minutes before meals; eat at consistent times |
| Aceclofenac | Empty stomach / spicy food | Increased GI irritation, peptic ulcer risk | Always take after food |
| Aceclofenac | Alcohol | Additive GI mucosal damage | Avoid alcohol |
| Amlodipine | Grapefruit / grapefruit juice | Inhibits CYP3A4 → increases amlodipine plasma levels → hypotension, flushing | Avoid grapefruit entirely |
| Pantoprazole | Food (general) | Food delays absorption slightly | Best taken 30 min before breakfast for maximum efficacy |
| Paracetamol | Alcohol | Additive hepatotoxicity (major concern given elevated bilirubin) | Strictly avoid alcohol |
| Cefoperazone | Alcohol | Disulfiram-like reaction - severe flushing, tachycardia, vomiting, hypotension | Absolute alcohol prohibition during and 72 hours after treatment |
| Trypsin-Chymotrypsin | Dairy products / antacids | May slightly reduce enzyme activity | Take on empty stomach or 30 min before food |
Summary of Key Clinical Alerts for Ramesh
| Priority | Alert |
|---|---|
| 🔴 Highest | Glimepiride + Aceclofenac → Hypoglycemia risk - monitor glucose closely |
| 🔴 Highest | Cefoperazone + Alcohol → Disulfiram-like reaction - absolute prohibition |
| 🔴 Highest | Paracetamol + elevated bilirubin → Monitor LFTs - limit dose to ≤ 2g/day |
| 🟡 Moderate | Aceclofenac + Amlodipine → Monitor BP daily |
| 🟡 Moderate | Pantoprazole + Glimepiride → Enhanced hypoglycemia |
| 🟡 Moderate | Amlodipine + Grapefruit → Avoid completely |
| 🟢 Counselling | All drugs except Chymoral Forte and Glimepiride → Take after food |
Convert this in small point
Drug-Drug Interactions (DDI)
🔴 Major
- Glimepiride + Aceclofenac → NSAID displaces sulfonylurea from protein binding → ↑ hypoglycemia risk → monitor glucose closely
- Aceclofenac + Amlodipine → NSAID causes Na⁺/water retention → ↓ antihypertensive effect → monitor BP daily
- Cefoperazone + Paracetamol → both hepatically metabolized → additive liver burden → monitor LFTs (bilirubin already 3.2 mg/dL)
🟡 Moderate
- Glimepiride + Cefoperazone → antibiotic potentiates insulin secretion → ↑ hypoglycemia risk → monitor glucose BD-TDS
- Pantoprazole + Glimepiride → PPI inhibits CYP2C19 → ↑ glimepiride levels → hypoglycemia risk
- Aceclofenac + Paracetamol → additive GI irritation → covered by pantoprazole → acceptable short-term
🟢 Minor
- Trypsin-Chymotrypsin + Cefoperazone → may enhance antibiotic tissue penetration → generally beneficial
Drug-Food Interactions (DFI)
- Glimepiride + Alcohol → severe hypoglycemia + flushing → strictly avoid alcohol
- Glimepiride + food → take 30 min before meals; eat at consistent times
- Aceclofenac + empty stomach/spicy food → GI irritation → always take after food
- Aceclofenac + Alcohol → additive GI mucosal damage → avoid alcohol
- Amlodipine + Grapefruit → inhibits CYP3A4 → ↑ amlodipine levels → hypotension → avoid grapefruit completely
- Pantoprazole + food → take 30 min before breakfast for best efficacy
- Paracetamol + Alcohol → additive hepatotoxicity → strictly avoid (bilirubin already high)
- Cefoperazone + Alcohol → disulfiram-like reaction → flushing, vomiting, hypotension → absolute prohibition during treatment and 72 hrs after
Top 3 Alerts for Ramesh
- 🔴 Hypoglycemia - Glimepiride + Aceclofenac + Cefoperazone all interact → monitor glucose frequently
- 🔴 No alcohol at all - Cefoperazone causes disulfiram reaction; paracetamol adds liver toxicity
- 🔴 Monitor LFTs - bilirubin already elevated + multiple hepatically metabolized drugs on board
This is a shared conversation. Sign in to Orris to start your own chat.